- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00002716
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective for metastatic colorectal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine, leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating patients who have unresectable liver metastases from colorectal cancer.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
OBJECTIVES:
- Compare the efficacy, toxicity, and cost of hepatic artery infusion of floxuridine, leucovorin calcium (CF), and dexamethasone vs IV fluorouracil and IV CF after resection of primary disease in patients with hepatic metastases secondary to colorectal cancer.
- Compare the quality of life of patients treated with these regimens.
- Measure the level of thymidylate synthase present in liver metastases, and correlate these levels with objective response and survival in patients treated with these regimens.
- Assess the p53 mutations, and correlate findings with objective response and survival in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, percentage of liver involvement on CT scan or MRI (less than 30% vs 30% to under 70%), prior chemotherapy (none vs adjuvant chemotherapy comprising fluorouracil (5-FU) and leucovorin calcium (CF) or 5-FU, CF, and levamisole (LEV) completed at least 1 year before study vs adjuvant chemotherapy comprising 5-FU with or without LEV completed at least 6 months before study), and synchronous disease (yes vs no). Patients are randomized to 1 of 2 treatment arms.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Westmead, New South Wales, Australien, 2145
- Westmead Hospital
-
-
-
-
Iowa
-
Cedar Rapids, Iowa, Forenede Stater, 52403-1206
- CCOP - Cedar Rapids Oncology Project
-
Des Moines, Iowa, Forenede Stater, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50309-1016
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Forenede Stater, 50316-2301
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Cancer Center at Mercy Medical Center-Des Moines
-
-
Nebraska
-
Papillion, Nebraska, Forenede Stater, 68128-4157
- Midlands Cancer Center at Midlands Community Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87131
- MBCCOP - University of New Mexico HSC
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44109
- MetroHealth Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, Forenede Stater, 19111-2497
- Fox Chase Cancer Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Forenede Stater, 54307-3453
- CCOP - St. Vincent Hospital Cancer Center, Green Bay
-
-
-
-
-
Lima, Peru, 34
- Instituto De Enfermedades Neoplasicas
-
-
-
-
-
San Juan, Puerto Rico, 00936-7344
- San Juan City Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
Unresectable liver metastases secondary to colorectal cancer
- Less than 70% liver involvement on CT scan or MRI
Liver biopsy required before study unless 1 of the following conditions are met:
- Carcinoembryonic antigen greater than 30
- 5 or more liver metastases visible on CT scan or MRI
- Greater than 50% to under 70% liver involvement on CT scan or MRI
Histologically proven primary colorectal cancer that is resected or appears resectable on CT scan and physical exam
- Documentation of previously resected primaries must be based on pathologic results of the resected tumor
Histological documentation of synchronous disease must be based on 1 of the following:
- Biopsy of primary colorectal tumor before study
- Suspicious lesion on barium enema, colonoscopy, or sigmoidoscopy, and a liver biopsy positive for adenocarcinoma consistent with the primary colorectal tumor
Measurable disease
- Clearly defined liver mass measuring at least 2 cm or at least 3 liver masses on CT scan or MRI
- No evidence of extrahepatic disease on CT scan and physical exam
- No portal vein occlusion or ascites
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Hepatic:
- Bilirubin no greater than 2 times normal
Other:
- No other malignancy within the past 5 years except inactive nonmelanomatous skin cancer, carcinoma in situ of the cervix, or grade 1 bladder cancer
- Not pregnant or nursing
- Fertile patients must use effective contraception
Chemotherapy:
- At least 1 year since prior adjuvant chemotherapy comprising fluorouracil (5-FU) and leucovorin calcium (CF) or 5-FU, CF, and levamisole (LEV)
- At least 6 months since prior adjuvant chemotherapy comprising 5-FU with or without LEV
- No other prior chemotherapy
- No other concurrent chemotherapy
Endocrine therapy:
No concurrent hormonal therapy except for nondisease-related conditions, e.g.:
- Steroids for adrenal failure
- Insulin for diabetes
- Intermittent dexamethasone as an antiemetic
Radiotherapy:
- No prior radiotherapy to the liver
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Arm I - laparotomy + conventional surgery + chemotherapy
Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months. Patients are followed every 3 months. |
|
Eksperimentel: Arm II - conventional surgery + chemotherapy
Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months. Patients are followed every 3 months. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Samlet overlevelse
Tidsramme: Op til 5 år
|
Op til 5 år
|
Tid til progression
Tidsramme: Op til 5 år
|
Op til 5 år
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: Nancy E. Kemeny, MD, Memorial Sloan Kettering Cancer Center
Publikationer og nyttige links
Generelle publikationer
- Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. doi: 10.1200/JCO.2005.03.8166. Epub 2006 Feb 27.
- Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003 Jun 1;63(11):2898-904.
- Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1(1):65-70. doi: 10.1038/sj.tpj.6500012.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Patologiske processer
- Neoplasmer
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Tyktarmssygdomme
- Tarmsygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Neoplastiske processer
- Kolorektale neoplasmer
- Neoplasma Metastase
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystem
- Anti-inflammatoriske midler
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Beskyttelsesagenter
- Mikronæringsstoffer
- Vitaminer
- Calciumregulerende hormoner og midler
- Modgift
- Vitamin B kompleks
- Dexamethason
- Fluorouracil
- Leucovorin
- Kalk
- Levoleucovorin
- Floxuridin
Andre undersøgelses-id-numre
- CALGB-9481
- U10CA031946 (U.S. NIH-bevilling/kontrakt)
- CDR0000064553 (Registry Identifier: NCI Physician Data Query)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kolorektal cancer
-
University of ArkansasAktiv, ikke rekrutterendeColorectal cancer og inflammatorisk tarmsygdomForenede Stater
-
University Health Network, TorontoAstraZenecaAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Leiomyosarkom | Mismatch Reparation Proficient Colorectal CancerCanada
-
Tianjin Medical University Cancer Institute and...RekrutteringMSI-H Advanced Colorectal CancerKina
-
Bristol-Myers SquibbAktiv, ikke rekrutterendeMikrosatellit stabil kolorektal cancer | Mismatch Reparation Proficient Colorectal Cancer | Mikrosatellit ustabil kolorektal cancer | Mismatch Reparation Manglende tyktarmskræftForenede Stater, Australien, Belgien, Canada, Irland, Italien, Spanien, Frankrig
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCAfsluttetMelanom | Ikke-småcellet lungekræft | Mismatch Reparation-Proficient Colorectal CancerForenede Stater
Kliniske forsøg med fluorouracil
-
CStone PharmaceuticalsAktiv, ikke rekrutterendeIkke-operabelt lokalt avanceret, tilbagevendende eller metastatisk spiserørspladecellecarcinomKina
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Fudan University; Peking University Cancer Hospital... og andre samarbejdspartnereUkendtNasopharyngealt karcinomKina
-
Sun Yat-sen UniversityUkendt
-
Actavis Inc.AfsluttetAktinisk keratoseForenede Stater
-
The Netherlands Cancer InstituteAfsluttet
-
The Netherlands Cancer InstituteAfsluttet
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedThe Hong Kong Anti-Cancer Society; hong Kong Cancer FundAfsluttet
-
The Cleveland ClinicNational Cancer Institute (NCI)AfsluttetAktinisk keratose | Organ- eller vævstransplantation; KomplikationerForenede Stater
-
Hokkaido Gastrointestinal Cancer Study GroupHokkaido University HospitalAfsluttet
-
Boston UniversityRekrutteringOverfladisk basalcellekarcinom | Planocellulært karcinom in situForenede Stater